PROKARIUM
2.3.2022 10:02:05 CET | Business Wire | Press release
Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, announced today it exercised its option with Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois — CHUV) for an exclusive, worldwide license for the use of Salmonella immunotherapy in the treatment of bladder cancer.
“This intellectual property is an important milestone for our lead oncology program as it enters clinical development in 2023 and also lays the groundwork for expanding Salmonella immunotherapy into other solid tumors,” said Livija Deban, PhD, Chief Scientific Officer of Prokarium. “Microbial immunotherapy is the gold standard-of-care in the treatment of bladder cancer. However, high recurrence rates and limited treatment options are currently available for patients. Prokarium is introducing a differentiated, efficacious microbial immunotherapy to a market that has seen little disruption in over 30 years.”
In exchange for the exclusive license, Prokarium will make an upfront payment, as well as additional payments upon achievement of development and commercialization milestones, and, if any product is approved, will pay royalties on net sales.
“Since initiating our collaboration with Prokarium in 2019, our team at the Department of Urology at CHUV has generated a robust preclinical data package demonstrating that Prokarium’s proprietary Salmonella bacteria generates quantitatively and qualitatively superior immune responses with different kinetics compared to the standard-of-care,” said Dr Denise Nardelli-Haefliger, Head of the Urology Research Unit. “Together with Prof Patrice Jichlinski, Prof Beat Roth, Dr Ilaria Lucca and Dr Sonia Domingos-Pereira, we are thrilled to see that the results of our collaboration have the potential to expand the disease-free interval and improve quality of life in patients with non-muscle invasive bladder cancer (NMIBC).”
About Non-Muscle Invasive Bladder Cancer (NMIBC)
Bladder cancer represents 5% of all new cancer cases in the US and accounts for 550,000 new cases yearly worldwide. The clinical staging is determined by the depth of invasion into the bladder wall. More than 70% of cases are diagnosed at an early stage, also known as non-muscle invasive bladder Cancer (NMIBC). Despite early diagnosis, the only approved therapies are Bacillus Calmette-Guérin (BCG), which often faces shortages, and chemotherapy, both delivered intravesically. Because of its high incidence and the limited number of treatment options, a huge unmet medical need remains in NMIBC.
About the Lausanne University Hospital - CHUV
The CHUV, Lausanne University Hospital, is one of the five university hospitals in Switzerland. With its 16 clinical and medico-technical departments and their numerous services, the CHUV is renowned for its academic achievements in health care, research, and teaching. The CHUV is also a well-known center of medical education and research thanks to its collaboration with the Faculty of Biology and Medicine of the University of Lausanne and the Swiss Federal Institute of Technology in Lausanne (EPFL). The CHUV has been recognized as one of the World’s 10 best hospitals according to the 2021 ranking of Newsweek magazine. It is with enthusiasm, that the Chairman of the Department of Urology, Prof Beat Roth, will pursue and support the research and studies with this novel treatment for bladder cancer.
About Prokarium
Prokarium is a biopharmaceutical company pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. Prokarium is based in London, UK. For further information, visit https://www.prokarium.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220302005063/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI-Driven Upgrade Cycle Expected to Fuel 8% Telecom Growth in 2026, NIQ Forecasts10.6.2026 13:00:00 CEST | Press release
On-device AI, ecosystem integration and premium innovation reshape global smart demand NIQ (NYSE: NIQ), a global leader in consumer intelligence, today released its 2026 Smartphone Forecast showing that an AI-driven upgrade cycle is expected to fuel 8% growth in the global telecom sector in 2026. As manufacturers accelerate investment in on-device AI and connected device ecosystems, consumers are increasingly prioritizing intelligence functionality, seamless integration, and premium experiences when choosing their next smartphone. The forecast suggests relatively stable conditions across the broader technology and durables market, with growth increasingly concentrated in premium segments. Europe is showing early signs of a new replacement cycle after two weaker years, while China is showing signals of modest growth despite subsidy rollbacks and a challenging comparison base. Insights from Mobile World Congress 2026 suggest a broader industry shift: smartphones are evolving from standal
Opensignal Expands Subscriber Analytics Solution, Available Globally10.6.2026 13:00:00 CEST | Press release
Now available across markets in Europe, Asia Pacific, Middle East, Africa, and the Americas Opensignal® today announced the global availability of Opensignal Subscriber Analytics™, extending the solution to operators across Europe, Asia Pacific, Middle East, Africa, and the Americas, subject to market-specific availability. Operators can contact Opensignal directly to confirm availability details in their specific markets of interest. Opensignal Subscriber Analytics measures competitive subscriber switching between operators at the local market level, alongside base market share by operator and region, using the same methodology Opensignal applies across its full measurement platform. Opensignal draws that measurement from hundreds of millions of subscriber devices globally. Until now, this capability has been available to operators in the United States and Canada. The global expansion makes it accessible to operators across all regions Opensignal serves. "Operators have strong visibil
Data Center World Unveils the Inaugural Data Center World Europe 202610.6.2026 13:00:00 CEST | Press release
Announces Conference Agenda, Leaders from NVIDIA and ClusterPower to Deliver Keynote AddressUnites the Innovators Shaping the Future of Digital Infrastructure 13-14 October 2026 in Vienna Data Center World, the premier event for the global data center ecosystem, unveils the launch of Data Center World Europe. Today, Data Center World Europe announces the Conference Agenda for the inaugural event. Over two days, Data Center World Europetackles the industry’s most urgent challenge: transforming Europe's data centre energy landscape. The event brings together leading operators, technologists, cloud providers, hyperscalers and energy management innovatorsto exchange actionable strategies and groundbreaking insights that drive measurable results. Attendees will leave equipped to overcome energy bottlenecks and drive the development of an AI-ready, sustainable future. Data Center World Europe takes place 13-14 October 2026 at VIECON – Vienna Congress & Convention Center in Vienna, Austria. I
SES to conduct share buyback transaction via acquisition of FDRs to meet obligations under its employee incentive programs10.6.2026 12:56:00 CEST | Press release
Publication of inside information pursuant to Article 17 of Regulation (EU) No 596/2014 (MAR) SES has decided to launch a buyback transaction for shares via acquisition of fiduciary depositary receipts (FDRs) to meet obligations under SES’s Equity Based Compensation Plan (EBCP). These FDRs will be repurchased on the basis of Article 430-15(3) of the law of 10 August 1915 on commercial companies, as amended, and will not be counted towards the 10% limit as authorized during the annual general meeting of shareholders held on April 2, 2026. Under this share buyback transaction via acquisitions of FDRs, SES may acquire up to 2,967,519 FDRs (ISIN LU0088087324) at market price for an aggregate amount not exceeding EUR 31,158,949.50. The share buyback transaction via acquisition of FDRs is expected to be completed before the date of the next annual general meeting of shareholders or sooner if the maximum number of repurchased shares is reached earlier. The buyback will be conducted in accorda
New Research Reveals the Next Wealth Management Divide: AI Rewards Firms Built to Scale10.6.2026 12:34:00 CEST | Press release
The market is entering a new phase where innovation alone is no longer a differentiator, and AI in particular risks widening operational gaps across banking, wealth and asset management. Weak foundations, poor execution and lack of strategic sourcing models are the structural barriers preventing institutions from translating technology investment into scalable, profitable growth.Key takeaways Leaders are significantly more likely to report profitability increases above 15%, demonstrating a direct link between scalability and financial performance. Integration issues across systems are identified as the single biggest barrier to scalable growth. Externalisation and as-a-service models are a primary lever of profitable scale, regardless of firm’s size. Competitive advantage will not come from where AI is deployed, but from how it is embedded and translated into business outcomes. The strategy is the sequence: foundations first, externalisation as accelerator, AI as amplifier. The next co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom